Ad26 Mos4 HIV vaccine - Janssen Vaccines and Prevention

Drug Profile

Ad26 Mos4 HIV vaccine - Janssen Vaccines and Prevention

Alternative Names: Ad26.Mos.1.Env + Ad26.Mos.2S.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol; Ad26.Mos4.HIV; Adenovirus serotype-26 mosaic-4 HIV vaccine; Adenovirus serotype-26 mosaic-4 human immunodeficiency virus vaccine; Tetravalent Ad26 Mos HIV

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Crucell Holland
  • Developer Janssen Vaccines and Prevention B.V
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 03 Nov 2017 Phase-II clinical trials in HIV infections (Prevention, In volunteers) in South Africa (IM) (NCT03060629)
  • 12 Oct 2017 Janssen Vaccines & Prevention B.V plans a phase I trial for HIV infections (Prevention) in USA (IM) (NCT03307915)
  • 31 Mar 2017 Janssen Vaccines & Prevention B.V. initiates the phase I/IIa IPCAVD-012 trial for HIV infections (Prevention) in USA (IM) (NCT02935686)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top